D. McMasters

发表

Multi-conformational Ligand Representation in 4D-QSAR: Reducing the Bias Associated with Ligand Alignment

Max Dobler, Angelo Vedani, Daniel R. McMasters, 2000 .

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

Synthesis of 2′-β-C-methyl-neplanocin derivatives as anti-HCV agents

M. Maccoss, G. Butora, D. Olsen, 2008 .

Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain.

K. Lyons, A. Weber, G. Kaczorowski, 2009, Bioorganic & medicinal chemistry letters.

Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

R. Sheridan, R. Nachbar, K. Korzekwa, 2007, Journal of medicinal chemistry.

Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.

J. Barrow, J. Vacca, S. Stauffer, 2003, Journal of medicinal chemistry.

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Nadine H. Elowe, Brian T. Campbell, J. Berger, 2017, Bioorganic & medicinal chemistry letters.

Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.

P. D. Cook, J. Tomassini, M. Maccoss, 2004, Journal of medicinal chemistry.

Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine.

M. Maccoss, G. Butora, D. Olsen, 2007, Bioorganic & medicinal chemistry.

The aromaticity of pyracylene: an experimental and computational study of the energetics of the hydrogenation of acenaphthylene and pyracylene.

T. Kiyobayashi, H. Diogo, J. F. Liebman, 2002, Journal of the American Chemical Society.

Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.

Lawrence C Kuo, Berta Strulovici, Daniel R McMasters, 2005, Bioorganic & medicinal chemistry letters.

P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.

Youwei Yan, L. Kuo, J. Vacca, 2005, Bioorganic & medicinal chemistry letters.

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.

J. Vacca, B. Wong, S. D. Lewis, 2004, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent and selective macrocyclic thrombin inhibitors.

Youwei Yan, J. Barrow, L. Kuo, 2003, Bioorganic & medicinal chemistry letters.

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.

Youwei Yan, L. Kuo, J. Vacca, 2003, Bioorganic & medicinal chemistry letters.

Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.

Lawrence C Kuo, Daniel R McMasters, Youwei Yan, 2008, Bioorganic & medicinal chemistry letters.

Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position.

Lawrence C Kuo, Daniel R McMasters, James C Barrow, 2003, Bioorganic & medicinal chemistry letters.

Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors.

S. D. Lewis, E. A. Lyle, J. Lynch, 2011, Bioorganic & medicinal chemistry letters.

Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group.

J. Barrow, J. Vacca, D. Colussi, 2004, Bioorganic & medicinal chemistry letters.

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Daniel R McMasters, James C Barrow, W. M. Sanders, 2003, Journal of medicinal chemistry.

Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.

Lawrence C Kuo, Daniel R McMasters, James C Barrow, 2004, Journal of medicinal chemistry.

9-hydroxyazafluorenes and their use in thrombin inhibitors.

Youwei Yan, B. Wong, P. Nantermet, 2005, Journal of medicinal chemistry.

Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

D. Hazuda, R. Cortese, J. Tomassini, 2003, Journal of Biological Chemistry.

Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.

Quanlai Song, Jie Xia, Daniel R McMasters, 2004, Journal of medicinal chemistry.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening.

Jeffrey C. Moore, M. Sturr, K. Gbewonyo, 2004, The Journal of organic chemistry.

Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.

Youwei Yan, J. Vacca, B. Wong, 2006, Bioorganic & medicinal chemistry.

Spectroscopy and reactivity of Kekulé hydrocarbons with very small singlet-triplet gaps.

J. Wirz, D. McMasters, 2001, Journal of the American Chemical Society.

Ochratoxin binding to phenylalanyl-tRNA synthetase: computational approach to the mechanism of ochratoxicosis and its antagonism.

A. Vedani, D. McMasters, 1999, Journal of medicinal chemistry.

Synthesis and biological evaluation of 5R- and 5S-methyl substituted D- and L-configuration 1,3-dioxolane nucleoside analogs.

W. Schleif, J. Tomassini, M. Maccoss, 2004, Bioorganic & Medicinal Chemistry.

Inhibitory Effect of 2′-Substituted Nucleosides on Hepatitis C Virus Replication Correlates with Metabolic Properties in Replicon Cells

J. Tomassini, M. Maccoss, G. Migliaccio, 2005, Antimicrobial Agents and Chemotherapy.

Dissecting Therapeutic Resistance to ERK Inhibition

L. Zawel, S. Fawell, L. Jayaraman, 2016, Molecular Cancer Therapeutics.

2,2-Dimethyl-2H-dibenzo[cd,k]fluoranthene, the First Kekulé Hydrocarbon with a Triplet Ground State

J. Wirz, D. McMasters, G. Snyder, 1997 .

Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening.

Daniel R McMasters, V. Maiorov, J. Lisnock, 2009, Bioorganic & medicinal chemistry letters.

Use of density functional calculations to predict the regioselectivity of drugs and molecules metabolized by aldehyde oxidase.

Jeffrey P. Jones, K. Korzekwa, R. A. Torres, 2007, Journal of medicinal chemistry.

Impact of pH on plasma protein binding in equilibrium dialysis.

K. Korzekwa, P. Lu, K. Koeplinger, 2008, Molecular pharmaceutics.

Extracellular loop C of NPC1L1 is important for binding to ezetimibe

W. Bildl, U. Schulte, M. E. Mccann, 2008, Proceedings of the National Academy of Sciences.

Smallest Maximum Intramolecular Distance: A Novel Method to Mitigate PXR Activation.

Brian Goldman, Xiaodan Zhang, Michael Bower, 2020, Journal of chemical information and modeling.

Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.

Daniel R. McMasters, J. Lisnock, R. DeVita, 2010, Bioorganic & medicinal chemistry letters.

Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5′-terminal phosphorylation both in vitro and in vivo

A. Willingham, A. Sachs, W. Flanagan, 2009, Nucleic acids research.

Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.

M. Struthers, D. Macneil, D. Cully, 2017, Bioorganic & medicinal chemistry letters.

Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Michael E. Lassman, M. Struthers, Qingzhong Hu, 2015, ACS medicinal chemistry letters.

Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.

Michael E. Lassman, Jeffrey T. Kuethe, M. Struthers, 2015, ACS medicinal chemistry letters.

Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system.

H Briem, A. Vedani, H. Briem, 2000, Journal of medicinal chemistry.

Identiﬁcation and Characterization of a Novel Nonsecosteroidal Vitamin D Receptor Ligand

P. Hodor, Nan Wei, J. Fisher, 2022 .

Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension.

M. Struthers, D. Macneil, D. Cully, 2017, ACS medicinal chemistry letters.

Impact of pH on plasma protein binding in equilibrium dialysis.

K. Korzekwa, P. Lu, K. Koeplinger, 2008, Molecular pharmaceutics.

Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain.

K. Lyons, A. Weber, G. Kaczorowski, 2009, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of isoxazoline voltage gated sodium channel blockers.

K. Lyons, A. Weber, G. Kaczorowski, 2009, Bioorganic & medicinal chemistry letters.